Insider Buying: Immuneering (NASDAQ:IMRX) Insider Buys $10,501.86 in Stock

Immuneering Corporation (NASDAQ:IMRX) insider Brett Matthew Hall acquired 2,298 shares of the firm’s stock in a transaction on Thursday, January 15th. The shares were acquired at an average price of $4.57 per share, with a total value of $10,501.86. Following the completion of the transaction, the insider directly owned 376,496 shares in the company, valued at approximately $1,720,586.72. This trade represents a 0.61% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Immuneering Price Performance

Shares of IMRX opened at $4.58 on Monday. The business’s 50-day moving average is $6.37 and its 200-day moving average is $5.82. The company has a market capitalization of $295.73 million, a price-to-earnings ratio of -2.57 and a beta of 0.48. Immuneering Corporation has a fifty-two week low of $1.10 and a fifty-two week high of $10.08.

Immuneering (NASDAQ:IMRX) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.01). Equities research analysts expect that Immuneering Corporation will post -1.86 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on IMRX shares. Leerink Partnrs upgraded Immuneering to a “strong-buy” rating in a research note on Friday, October 31st. Oppenheimer raised their target price on Immuneering from $21.00 to $30.00 and gave the company an “outperform” rating in a report on Thursday, September 25th. Chardan Capital reiterated a “buy” rating and set a $20.00 price target on shares of Immuneering in a research note on Thursday, November 13th. Wall Street Zen lowered Immuneering from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Finally, Mizuho set a $12.00 target price on Immuneering in a report on Wednesday, October 29th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $16.50.

Institutional Trading of Immuneering

A number of institutional investors have recently bought and sold shares of the business. Jane Street Group LLC bought a new position in shares of Immuneering during the 1st quarter valued at about $32,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Immuneering in the third quarter valued at $35,000. Future Financial Wealth Managment LLC bought a new stake in Immuneering during the third quarter worth $35,000. Kingsview Wealth Management LLC acquired a new stake in Immuneering in the second quarter valued at $47,000. Finally, Mercer Global Advisors Inc. ADV bought a new position in shares of Immuneering in the 3rd quarter valued at about $70,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.